| Document |
Document Title |
|
WO/2019/176505A1 |
[Problem] To develop a compound which exhibits high accumulation in cancer cells and can emit α rays, and to provide a pharmaceutical composition for cancer treatment that contains said compound. [Solution] A pharmaceutical composition ...
|
|
WO/2019/175019A1 |
A biotin derivative of formula (I) (I) in which R is a peptide with the sequence VHPKQHRGGSKGC, linked to the succinimidyl ring through the -SH group of the C-terminal cysteine, which can be used in a method for detecting early atheroscl...
|
|
WO/2019/169445A1 |
A flexible brachytherapy device (1), comprising a bioresorbable carrier matrix structure (2) comprising a plurality of radio-isotope particles (3) and having opposite first surface and second surfaces. The bioresorbable carrier matrix st...
|
|
WO/2019/169815A1 |
A radioactive molecular probe and an application thereof in detection of intravital islets, its structure is: formula (I), wherein R 1 are halogen, saturated aliphatic hydrocarbon group, unsaturated aliphatic hydrocarbon group and aromat...
|
|
WO/2019/173639A1 |
The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.
|
|
WO/2019/168170A1 |
The purpose of the present invention is to provide a compound having high binding specificity for amyloid proteins and high blood-brain barrier permeability, and featuring rapid elimination from normal tissues. The present invention rela...
|
|
WO/2019/169241A1 |
The present invention discloses a method of selectively providing radiation dosimetry to equine or other hooved animals ("ungulates") in need of such treatment. The radiation emitting compound is applied to the lamina of the hoof through...
|
|
WO/2019/169289A1 |
Low dose radiation, including conversion electron energy induces apoptosis in peripheral macrophages and CNS microglia. The transport of Sn-117m, a conversion electron emitter has been shown to be deliverable into the CNS across the bloo...
|
|
WO/2019/165171A2 |
Compounds and methods are described herein that are useful in brachytherapy. A compound of the present invention may comprise: a cancer cell targeting agent (e.g., transferrin); a protecting group; a cross-linking moiety; and an enzyme (...
|
|
WO/2019/165200A1 |
A compound of Formula (I) or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt wherein the definitions of R1-R13 and L1-L4 are provided i...
|
|
WO/2019/156726A1 |
Disclosed herein are high Tm RNA nanostructures that can be composed of one or more modules or motifs to build RNA nanostructures with or without layers. The RNA nanostructures can have a core domain and three or more double-stranded arm...
|
|
WO/2019/157037A1 |
Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule ra...
|
|
WO/2019/151384A1 |
One embodiment of the present invention relates to novel substances, etc., which are: [1] a compound, etc., represented by formula (A1) or formula (B1); [2] a compound, etc., represented by formula (A2) or formula (B2); [3] a compound, e...
|
|
WO/2019/152318A1 |
The present invention relates to Fc binding proteins comprising one or more domains with Cysteine in the C-terminal helical region. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. T...
|
|
WO/2019/151827A1 |
The present invention relates to a bilirubin derivative-based diagnostic and therapeutic ultrasound contrast agent. Fine particles comprising a bilirubin derivative according to the present invention react sensitively to reactive oxygen ...
|
|
WO/2019/152958A1 |
Provided herein are methods of fluorinating organic compounds. The electrochemical fluorination and radiofluorination of organic molecules using the cation pool technique is described, where the 18F and/or 19F-fluorine ions are added aft...
|
|
WO/2019/145293A1 |
The present application relates to a diagnostic composition comprising: a. a compound of Formula I, b. ethanol, c. water, and d. a hydroxycarboxylic acid, a salt of a hydroxycarboxylic acid or a mixture thereof. The diagnostic compositio...
|
|
WO/2019/145384A1 |
The invention comprises radiolabeled oligonucleotide of the formula (I) wherein n, X1, X2, the linker 1, the linker 2, Q and the receptor targeting moiety are as defined I the description. The radiolabeled oligonucleotides of the formula...
|
|
WO/2019/145292A1 |
The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies usin...
|
|
WO/2019/145294A1 |
The present invention relates to a novel method of preparing a compound of the formula I. Diagnostic compositions and their use in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's ...
|
|
WO/2019/147912A1 |
The present invention is directed to radiopharmaceuticals with improved stability, a kit, and a method of production thereof.
|
|
WO/2019/145291A1 |
The present invention relates to novel compounds of the formula (II) and formula (III) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and othe...
|
|
WO/2019/142853A1 |
The purpose of the present invention is to provide a method for causing exosomes to contain an arbitrary protein, lipid, carbohydrate, or nucleic acid. The above problem can be solved by a method for producing exosomes that includes (a) ...
|
|
WO/2019/136469A1 |
Systems and methods are disclosed for quantifying blood flow using time-varying kinetic modeling of high temporal-resolution dynamic positron emission tomography (PET) data. A single tracer is introduced into the body. A first set of ima...
|
|
WO/2019/133799A1 |
Disclosed herein are monoclonal antibodies targeting specific tau epitopes, particularly, microtubule binding domain region 2 or region 4. Also disclosed herein are antibodies or antigen binding fragments thereof that specifically recogn...
|
|
WO/2019/132613A1 |
The present invention can provide a contrast medium specifically binding to vascular endothelial cells. To this end, a contrast medium specifically binding to vascular endothelial cells, according to the present invention, can contain a ...
|
|
WO/2019/109046A9 |
The present invention relates to photoactivatable compounds and methods of use thereof for determining binding site and other structural information about RNA transcripts. The invention also provides methods of identifying RNA transcript...
|
|
WO/2019/133853A1 |
Provided herein are HLA-PEPTIDE targets and antigen binding proteins that bind HLA- PEPTIDE targets. Also disclosed are methods for identifying the HLA-PEPTIDE targets as well as identifying one or more antigen binding proteins that bind...
|
|
WO/2019/131998A1 |
The present invention addresses the problem of providing an astatine solution that can be used in radionuclide therapy for the treatment of thyroid disease or the like, and a method for producing the same. The present invention provides:...
|
|
WO/2019/108135A9 |
A method for the prognosis of response to treatment for a patient suffering from cancer, the method comprising: measuring the expression of at least one immune marker in a leukocyte sample taken from the patient with cancer; classifying ...
|
|
WO/2019/132117A1 |
The present invention provides a precursor compound for preparing a radioactive compound for efficiently imaging a heart, a radioactive compound prepared by using the precursor compound, and a use thereof as a contrast agent for PET imag...
|
|
WO/2019/131458A1 |
Provided are a compound represented by formula (1) or a salt thereof, and a medicine including the same. [In the formula, X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represent...
|
|
WO/2019/133639A2 |
In certain embodiments internalizing anti-CD146 antibodies and conjugates thereof are provided. It was discovered that anti-CD146 antibodies are capable of targeting both epithelioid and sarcamatous subtypes of mesothelioma cells. In cer...
|
|
WO/2019/122255A1 |
The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known c...
|
|
WO/2019/125982A1 |
Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.
|
|
WO/2019/120063A1 |
Provided is an improved pH low insertion peptide which is obtained by repeating the sequence of an extracellular domain of a pH low inversion peptide existing in the prior art one or more times on the basis of the sequence of the pH low ...
|
|
WO/2019/126497A1 |
The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue via 18F- labeled peptide ligands disclosed herein.
|
|
WO/2019/123409A1 |
Multinuclear complexes and methods for preparing them are provided. The discrete multinuclear complexes include a one or more transition metals and a radioisotope having the same coordination geometry as the transition metal. A bridging ...
|
|
WO/2019/125153A1 |
The present invention relates to methods for preparing a cell targeting conjugate, which conjugate comprises a cell binding moiety conjugated to a secondary functional moiety. The present invention further relates to the cell targeting c...
|
|
WO/2019/115429A1 |
The invention relates to compounds according to the general formula (I) or a pharmaceutically acceptable salt of an inorganic or organic acid, a hydrate, a stereoisomer or a solvate thereof, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 a...
|
|
WO/2019/115684A1 |
The present invention relates to complexes comprising a prostate- specific membrane antigen (PSMA) targeting compound linked to a radionuclide, such as 212Pb or 227Th, through a TCMC or DOTA chelating moiety. These compounds, and pharmac...
|
|
WO/2019/115547A1 |
The present disclosure relates to imaging and endoradiotherapy of diseases involving prostate-specific membrane antigen (PSMA). Provided are compounds which bind or inhibit PSMA and furthermore carry at least one moiety which is amenable...
|
|
WO/2019/110845A1 |
The present invention provides a radiotracer comprising a progastrin moiety, a chelating moiety and a radioisotope. Uses of said biomarker for imaging and detecting cancers in a subject are also provided. In one embodiment, the radiotrac...
|
|
WO/2019/113031A1 |
Methods for treating a proliferative disease in a patient having a p53 mutation by administering an effective amount of an immunotherapy which includes a targeting agent for an epitope of CD33. The proliferative disease may be a hematolo...
|
|
WO/2019/112271A2 |
The present invention aims to provide a method for obtaining diagnostic information of lung disease wherein the lung is imaged by optical diffuse spectroscopy using a diagnostic composition and the obtained optical diffuse spectroscopic ...
|
|
WO/2019/113041A1 |
Methods for treating a proliferative disease in hematologic malignancy in a subject having a complex karyotype by administering an effective amount of an immunotherapy which includes a targeting agent for an epitope of CD33. The prolifer...
|
|
WO/2019/113449A1 |
The present invention is directed to the use of radiolabeled ligands of leukocyte function-associated antigen~1 (LFA~1 ) receptor in order to image and quantify leukocyte activation, recruitment and in vivo trafficking of tumor infiltrat...
|
|
WO/2019/108689A1 |
The invention provides antibody formulations and methods useful for prophylaxis or treatment of transthyretin-related amyloidosis.
|
|
WO/2019/105913A1 |
The present invention relates to radiolabelled 4-(furo[3,2-c]pyridin-4-yl) derivatives and their use as radioactive tracers, and in particular their use as imaging agents.
|
|
WO/2019/100973A1 |
Provided are a glutamate polypeptide-estrogen/anti-estrogen conjugate, synthesis method therefor, composition thereof, and reagent kit. The conjugate comprises a polypeptide and an estrogen or anti-estrogen; the estrogen or anti-estrogen...
|
